Search clinical trials for: Immunogenic Factors

Total 33841 results

Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PNEU-PATH)

Pneumococcal Infections

United States, Korea, Republic of, Spain, Taiwan
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Cytomegalovirus Infections
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

HIV Infections | Pneumococcal Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

HIV Infections

United States
Enimmune Corporation

Completed

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Enterovirus Infections

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

HIV Infections

United States, Brazil, Haiti, Jamaica, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

HIV Infections

United States
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

Pneumococcal Disease

Korea, Republic of
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of
Pfizer

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Infections, Meningococcal

Australia, Canada, Czechia, Panama, South Africa, Turkey
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Mumps

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
International Vaccine Institute
Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.

Completed

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Typhoid

Philippines
International Vaccine Institute
Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.

Completed

Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine

Typhoid

Philippines
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Mumps

China
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Human Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention

United States
Universidad del Desarrollo
Pontificia Universidad Catolica de Chile; University of Chile; Ministry of Health...

Active, not recruiting

Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster (REFUERZO)

Covid19

Chile
Sinovac Biotech Co., Ltd
Guangdong Center for Disease Prevention and Control

Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Hand, Foot and Mouth Disease

China
Sinovac Biotech Co., Ltd

Withdrawn

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

Infection, Viral, Enterovirus

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China
Sinovac Biotech Co., Ltd
Shaanxi Provincial Center for Disease Control and Prevention

Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

Hand, Foot and Mouth Disease

China
Sinovac Biotech Co., Ltd
Shandong Province Centers for Disease Control and Prevention

Completed

Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Hand, Foot and Mouth Disease

China
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Sinovac Research and Development Co., Ltd.

Completed

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Covid19

China
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
Dynavax Technologies Corporation

Completed

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Estonia, Canada
GlaxoSmithKline

Completed

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Herpes Zoster | Herpes Zoster Vaccine

United States, Canada, Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
U.S. Army Medical Research and Development Command

Enrolling by invitation

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Tularemia

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (PNEU-AGE)

Pneumococcal Infections

Taiwan, United States, Canada, Japan, Spain
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Norwalk Gastroenteritis | Norovirus Infections

China
GlaxoSmithKline

Completed

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Respiratory Disorders

Belgium
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Pneumococcal Infections

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Juvenile Idiopathic Arthritis

Japan

3

Subscribe